NWP 102
Alternative Names: NWP-102Latest Information Update: 04 Jan 2023
At a glance
- Originator NEUWAY Pharma
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Canavan disease
Most Recent Events
- 28 Nov 2022 NWP 102 is available for licensing as of 28 Nov 2022. https://www.neuway-pharma.com/partnering/
- 28 Nov 2022 NEUWAY Pharma has patent protection for EnPC® as a versatile and modular drug delivery platform (NEUWAY Pharma website, November 2022)
- 28 Nov 2022 Early research in Canavan disease in Germany (IV) (NEUWAY Pharma pipeline, November 2022)